期刊文献+
共找到14篇文章
< 1 >
每页显示 20 50 100
Genitourinary small-cell carcinoma: 11-year treatment experience 被引量:5
1
作者 Kun Chang 《Asian Journal of Andrology》 SCIE CAS CSCD 2014年第5期705-709,I0007,共6页
The predictive factors of prognosis and treatment strategies for small-cell carcinoma (SCC) of the urinary tract are controversial. This study was aimed to investigate the clinical experience and management of patie... The predictive factors of prognosis and treatment strategies for small-cell carcinoma (SCC) of the urinary tract are controversial. This study was aimed to investigate the clinical experience and management of patients with SCC of the urinary tract. We collected data of patients who were diagnosed with genitourinary SCC (GSCC) between 2002 and 2013 and were treated in the Fudan University Shanghai Cancer Center. A total of 18 patients were diagnosed with GSCC of which 10 originated from the prostate, seven from the bladder and one from the adrenal gland. The mean follow-up time was 15.5 months and progression-free survival (PFS) was 9.3 months. Primary tumor resection was attempted in 13 of 18 patients (72.2%) in whom radical surgery was performed in six of 14 (42.9%) limited disease patients. Most of the patients (13, 72.2%) received cisplatin-based chemotherapy. Patients who had normal lactic dehydrogenase (LDH) levels showed a significantly higher median PFS and overall survival (OS) compared with patients with high LDH levels (P = 0,030, P = 0.010). Patients with limited disease treated with a radical operation experienced a non-significant (P = 0,211) longer PFS compared with patients who were not treated, but this reached statistical significance after analyzing OS (P = 0.211, P = 0.039). Our patients showed a poor prognosis as reported previously. Serum LDH levels beyond the normal range indicate a poor prognosis. For GSCC patients who are diagnosed with limited disease, radical surgery is strongly recommended along with cisplatin-based chemotherapy, 展开更多
关键词 bladder cancer DIAGNOSIS genitourinary small-cell carcinoma PROGNOSIS prostate cancer
下载PDF
Small-cell neuroendocrine carcinoma of the prostate: are heterotransplants a better experimental model? 被引量:2
2
作者 Lluis-A. Lopez-Barcons 《Asian Journal of Andrology》 SCIE CAS CSCD 2010年第3期308-314,I0007,共8页
Small-cell neuroendocrine carcinoma of the prostate (SCNCP) is an uncommon type of prostate cancer. However, it is of clinical importance because it is one of the most aggressive tumors of the prostate with a very p... Small-cell neuroendocrine carcinoma of the prostate (SCNCP) is an uncommon type of prostate cancer. However, it is of clinical importance because it is one of the most aggressive tumors of the prostate with a very poor prognosis. There exist few artificially cultured tumor cell lines to study SCNCE Then, another approach to that study consists in the use of fresh tumor tissue obtained from patients and its heterotransplantation into host mice. The purpose of this review is to integrate data from more than 20 years of heterotransplantation research in the study of small-cell neuroendocrine carcinoma of the prostate (SCNCP). Heterotransplantation has provided data regarding the histopathology, karyotype, DNA content, cell cycle frequency, tumor markers, androgen receptor expression, metastasis and take rate of this prostate disease. When possible, comparisons between original in situ specimens removed from patients and heterotransplanted tissue from host mice have been made. There are advantages, as well as limitations, that have been identified for SCNCP heterotransplants versus xenotransplantation of cultured cells. Overall, heterotransplanted tumors are better than conventional tumor xenografts at retaining tumor morphology, pathology, secretory activity and expression of tumor markers of the patient's original specimen. Furthermore, heterotransplanted tissue preserves the three-dimensional tumor architecture of the prostate to maintain critical stromal-epithelial cell interactions. 展开更多
关键词 heterotransplant nude mice PROSTATE small-cell neuroendocrine carcinoma XENOTRANSPLANT
下载PDF
Small-cell neuroendocrine carcinoma of the rectum—a rare tumor type with poor prognosis:A case report and review of literature 被引量:3
3
作者 Zhen-Zhou Chen Wang Huang Zheng-Qiang Wei 《World Journal of Clinical Cases》 SCIE 2020年第23期6095-6102,共8页
BACKGROUND Small-cell neuroendocrine carcinoma(SNEC)of the rectum is a rare tumor associated with poor prognosis.CASE SUMMARY We report a case of a 77-year-old male who came into our hospital because of blood with his... BACKGROUND Small-cell neuroendocrine carcinoma(SNEC)of the rectum is a rare tumor associated with poor prognosis.CASE SUMMARY We report a case of a 77-year-old male who came into our hospital because of blood with his stool.An endoscopy revealed a cauliflower-like neoplasm in his rectum.Imaging examination showed that the lesion in the upper rectum was likely rectal cancer,and there was no evidence of metastasis.The patient was treated with surgery.Pathological examination confirmed SNEC of the rectum and an R0 resection was achieved.However,1 mo after the operation,the patient developed intestinal and ureteral obstructions due to peritoneal metastases.Finally,the patient died from renal failure.CONCLUSION SNEC of the rectum is a high-grade carcinoma with an aggressive phenotype,and surgery should be cautiously considered. 展开更多
关键词 Case report small-cell neuroendocrine carcinoma RECTUM TREATMENT PROGNOSIS Rare tumor
下载PDF
Small-Cell Carcinoma of Prostate:A Case Report and Literature Review
4
作者 Feng Sun Chun-lin Chen +3 位作者 Rong-jian Chen Ai-e Liu Ling Ding Xiao-zhe Cao 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2010年第3期231-234,共4页
One case of small-cell carcinoma(SCC) of prostate was identified at Shangyu people's hospital.This 70-year-old male had a prior diagnosis of prostatic adenocarcinoma when he was first admitted to the hospital and r... One case of small-cell carcinoma(SCC) of prostate was identified at Shangyu people's hospital.This 70-year-old male had a prior diagnosis of prostatic adenocarcinoma when he was first admitted to the hospital and received anti-androgen treatment.9 months later,he was readmitted to the hospital and was diagnosed as SCC through biopsy.The article was written to evaluate the clinical and pathological characteristics and treatment of SCC of prostate. 展开更多
关键词 small-cell carcinoma Prostatic neoplasms
下载PDF
A Novel Peptide from T-Cell Leukemia Translocation-Associated Gene (TCTA) Protein Inhibits Proliferation of a Small-Cell Lung Carcinoma
5
作者 Shigeru Kotake Toru Yago, Manabu Kawamoto Yuki Nanke 《Journal of Cancer Therapy》 2013年第8期44-46,共3页
In 2009, we demonstrated that a peptide, which we named “Peptide A”, derived from the extracellular domain of T-cell leukemia translocation-associated gene (TCTA) protein, inhibited both RANKL-induced human osteocla... In 2009, we demonstrated that a peptide, which we named “Peptide A”, derived from the extracellular domain of T-cell leukemia translocation-associated gene (TCTA) protein, inhibited both RANKL-induced human osteoclastogenesis and pit formation of mature human osteoclasts. Here, we examined the effect of Peptide A on the cell proliferation of cell lines of small-cell lung carcinoma, breast cancer, and prostate cancer: RERF-LC-MA, MCF-7, and PC-3, respectively. Peptide A inhibited the proliferation of RERF-LC-MA, but not MCF-7 or PC-3. TCTA protein was immunohistologically detected in RERF-LC-MA and MCF-7. Thus, Peptide A may provide a novel strategy for the therapy of the patients with small-cell lung carcinoma, especially with bone metastasis. In addition, Peptide A may be useful for the treatment of various cancer patients with bone metastasis. 展开更多
关键词 OSTEOCLAST small-cell LUNG carcinoma TCTA
下载PDF
Fulminant hepatic failure resulting from small-cell lung cancer and dramatic response of chemotherapy 被引量:1
6
作者 Kyoichi Kaira Atsushi Takise +1 位作者 Rieko Watanabe Masatomo Mori 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第15期2466-2468,共3页
Prompt treatment in tumor-associated encephalopathy may prolong survival. We describe a 69-year-old male patient who was presented with fulminant hepatic failure, secondary to small-cell lung carcinoma with rapidly pr... Prompt treatment in tumor-associated encephalopathy may prolong survival. We describe a 69-year-old male patient who was presented with fulminant hepatic failure, secondary to small-cell lung carcinoma with rapidly progressing encephalopathy. Both symptoms remitted following chemotherapy, suggesting swift diagnosis and administration of chemotherapy to be effective in treatment of fulminant hepatic failure and encephalopathy. 展开更多
关键词 small-cell lung carcinoma Fulminant hepatic failure CHEMOTHERAPY
下载PDF
SURGICAL TREATMENT OF PRIMARY ESOPHAGEAL SMALLCELL CARCINOMA 被引量:1
7
作者 王永岗 汪良骏 +2 位作者 张德超 张汝刚 张大为 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2000年第1期75-78,共4页
Objective: To study the clinical biocharacteristics of primary esophageal small-cell carcinoma (PESC) and factors influencing prognosis and to find rational indications for combination therapy. Methods: To analyze the... Objective: To study the clinical biocharacteristics of primary esophageal small-cell carcinoma (PESC) and factors influencing prognosis and to find rational indications for combination therapy. Methods: To analyze the clinical materials of 47 patients who had undergone an operation with PESC and to compare it with those patients with esophageal squamous-cell carcinoma (ESCC) or primary esophageal adenocarcinoma (PEAC). Results: The overall resectability, morbidity and 30-day mortality rates of PESC were 93.6%, 17.0% and 2.1% respectively, similar to those of ESCC or PEAC. TNM staging and lymph node metastasis were the major determinants influencing long-term survival. Tumor length, depth of tumor invasion and type of operation had little influence on long-term prognosis. The 5-year survival rate of PESC was 7.5%, which was much lower than that of ESCC and PEAC (P<0.01). Among the 42 deceased patents, one died of anastomotic leakage and the others died of remote metastasis and recurrence. Adjuvant chemotherapy did not help improve the patients’ long-term survival. Conclusions: Compared with ESCC and PEAC, PESC is the most malignant type with early lymphatic and hematogenous metastases and poor prognosis. Lymph node metastasis is the major factor influencing the prognosis. Patients in stage 0, I and II a of PESC are indicated for surgical resection, while those in stage II b, III or IV should be managed with non-surgical combined therapy. 展开更多
关键词 Esophageal carcinoma small-cell carcinoma Squamous-cell carcinoma ADENOcarcinoma PROGNOSIS
下载PDF
泌尿生殖系相关的多原发癌11例报告 被引量:2
8
作者 南勋义 党建功 +2 位作者 陈兴发 李永海 王武生 《临床泌尿外科杂志》 1997年第1期9-11,共3页
报告1985~1995年间诊治的与泌尿生殖系相关的多原发癌11例,并结合文献重点强调多原发癌有别于晚期转移癌,它是人体内同时或异时存在的两种或两种以上各自独立的原发癌。认为如能及早积极手术治疗并辅以其他疗法,其预后不比单发癌差。
关键词 泌尿生殖器肿瘤 多原发癌 病例报告
下载PDF
11例泌尿生殖相关多原发癌的报告
9
作者 南勋义 党建功 +2 位作者 陈兴发 李永海 王武生 《现代泌尿外科杂志》 CAS 1996年第1期14-17,共4页
本文报告我科1985年~1995年间11例与泌尿器官相关的多原发癌。结合文献重点强调多原发癌有别于晚期转移癌,它是人体内同时或异时存在的两种或两种以上各自独立的原发癌,如能及早积极手术治疗辅以其他疗法则其预后不比单原发癌差。并对... 本文报告我科1985年~1995年间11例与泌尿器官相关的多原发癌。结合文献重点强调多原发癌有别于晚期转移癌,它是人体内同时或异时存在的两种或两种以上各自独立的原发癌,如能及早积极手术治疗辅以其他疗法则其预后不比单原发癌差。并对其发病率、病因及可能的发病机制等进行了讨论。 展开更多
关键词 泌尿器官 病因 发病机制
下载PDF
相关泌尿系的多原发癌5例报告 被引量:1
10
作者 余忠健 王晓华 +1 位作者 陈立武 冯寿 《伤残医学杂志》 2000年第2期25-27,共3页
多原发恶性肿瘤是指同一宿主的单个或多个器官同时或先后发生两个或两个以上原发性恶性肿瘤.近10多年来由于检治癌症的仪器B超、CT、MRI的普遍应用到临床上,癌症的早期发现、早期治疗有了明显提高,还因患者寿命延长,故对多... 多原发恶性肿瘤是指同一宿主的单个或多个器官同时或先后发生两个或两个以上原发性恶性肿瘤.近10多年来由于检治癌症的仪器B超、CT、MRI的普遍应用到临床上,癌症的早期发现、早期治疗有了明显提高,还因患者寿命延长,故对多原发癌的发现也随之增加. 本文报告5例相关泌尿系的多原发癌:男性4例,女性1例;年龄从46岁~74岁,平均62岁,第一原发癌诊疗后至第二原发癌出现为3个月~8年,平均58.2个月,其中1例在第二原发癌治疗后,2年再生第三原发癌.第一原发癌为肾透明细胞癌、膀胱移行细胞癌、右肾上腺无功能皮质癌,在治疗后的5年、6年、3个月出现结肠癌,胃中分化腺癌及食道上段鳞癌;第一原发癌为左乳腺癌、胃癌在治疗后的5年、8年出现右肾盂癌,膀胱乳头状癌. 本文还讨论了多原发癌病人与机体免疫缺陷,化疗后药物诱发,放疗后引起放射性二重病及年老病人机体抵抗力,免疫力下降有关.对于多原发癌的病人,由于癌肿互为独立性,积极的手术治疗,可使病人延长生命,提高生活质量.证实陈氏报告第一原发癌为消化道癌而后发生尿路上皮癌者预后比先发生尿路上皮癌后发生消化道癌者好.临床医生在诊断、治疗及追问病史中,应警惕第二原发癌的存在;对无法手术的病例? 展开更多
关键词 多原发癌 泌尿系 治疗 CT MRI B超
下载PDF
Neuroendocrine carcinoma of the cervix:A comprehensive clinicopathologic study and literature review
11
作者 Xiaobo Zhang Mingzhu Li +1 位作者 Guo Zhang Danhua Shen 《Gynecology and Obstetrics Clinical Medicine》 2023年第3期163-169,共7页
Aims Neuroendocrine carcinoma of the cervix(NECC)is a rare variant of cervical cancer.This study aims to investigate the clinicopathological features and prognosis of NECC.Methods A retrospective analysis was conducte... Aims Neuroendocrine carcinoma of the cervix(NECC)is a rare variant of cervical cancer.This study aims to investigate the clinicopathological features and prognosis of NECC.Methods A retrospective analysis was conducted on twenty-one patients diagnosed with NECC between May 2008 and September 2021at Peking University People's Hospital.The study involved histopathological examination,immunohistochemistry,ThinPrep cytology test(TCT),and high-risk HPV hybrid capture 2(HC2)assay.Follow-up was conducted through telephone interviews and medical records for a range of 3–160 months,with an average follow-up period of 49.8 months.Results The average age of the patients was 48.6 years(range:33–69 years).Seventeen patients were diagnosed with neuroendocrine carcinoma through biopsy.Nine cases underwent TCT and HC2 tests before biopsy,and TCT results of four cases showed high-grade squamous intraepithelial lesion(HSIL).High-risk HPV(HR-HPV)positive was detected in seven cases.The cancer cells exhibited consistent morphological features,including sparse cytoplasm,intensely stained nuclei,and extensive neoplastic necrosis.Thirteen cases were classified as pure NECC(61.9%),while eight cases were mixed types(38.1%).Three cases were associated with squamous cell carcinoma(SCC),and five cases were associated with adenocarcinoma.Prognosis varied significantly among these subtypes(p<0.05).The overall survival rate in the follow-up period was 66.7%(12/18).Conclusions NECC is an extremely rare and highly aggressive tumor with a poor prognosis,particularly in cases of mixed histology.It is strongly associated with HPV infection.TCT and HPV testing significantly enhance the detection rate before the biopsy.The diagnosis of NECC relies on histological and immunohistochemical examinations.This study provides valuable clinical observations on NECC and emphasizes the importance of early detection and accurate diagnosis for improved patient outcomes. 展开更多
关键词 Neuroendocrine carcinoma CERVIX small-cell neuroendocrine carcinoma PATHOLOGY Clinicopathological features IMMUNOHISTOCHEMISTRY Prognosis
原文传递
2023 ASCO-GU尿路上皮癌精粹解读 被引量:1
12
作者 鲍一歌 韩苏军 黄海 《中华泌尿外科杂志》 CAS CSCD 北大核心 2023年第4期251-254,共4页
2023年美国临床肿瘤学会泌尿男生殖系肿瘤研讨会(ASCO-GU)报告多项尿路上皮癌进展。新方案应用于非肌层浸润性膀胱癌(NMIBC)治疗, 为卡介苗抵抗/失败NMIBC提供更多选择。肌层浸润性膀胱癌(MIBC)围手术期治疗中, CheckMate274研究3年随... 2023年美国临床肿瘤学会泌尿男生殖系肿瘤研讨会(ASCO-GU)报告多项尿路上皮癌进展。新方案应用于非肌层浸润性膀胱癌(NMIBC)治疗, 为卡介苗抵抗/失败NMIBC提供更多选择。肌层浸润性膀胱癌(MIBC)围手术期治疗中, CheckMate274研究3年随访数据显示纳武利尤单抗辅助治疗组无疾病生存率优势。转移性尿路上皮癌(mUC)方面, IMvigor130研究总生存率(OS)报告发布, 引发mUC一线治疗思考。会议还关注上尿路尿路上皮癌(UTUC)研究。 展开更多
关键词 尿路上皮癌 非肌层浸润性膀胱癌 肌层浸润性膀胱癌 肿瘤免疫治疗 ASCO-GU会议
原文传递
肾移植受者新发泌尿及男性生殖系统恶性肿瘤的生存分析 被引量:8
13
作者 苗芸 于立新 +7 位作者 邓文锋 杜跃军 付绍杰 徐健 杜传福 王亦斌 魏强 叶桂荣 《中华泌尿外科杂志》 CAS CSCD 北大核心 2010年第3期175-178,共4页
目的探讨肾移植受者发生泌尿及男性生殖系统恶性肿瘤的预后。方法分析31例肾移植术后新发泌尿及男性生殖系统恶性肿瘤患者的临床资料,肾癌(原肾)6例,肾盂输尿管癌(原肾)4例,膀胱癌14例,前列腺癌7例。并与31例年龄相同、肿瘤分... 目的探讨肾移植受者发生泌尿及男性生殖系统恶性肿瘤的预后。方法分析31例肾移植术后新发泌尿及男性生殖系统恶性肿瘤患者的临床资料,肾癌(原肾)6例,肾盂输尿管癌(原肾)4例,膀胱癌14例,前列腺癌7例。并与31例年龄相同、肿瘤分期相同的普通泌尿及男性生殖系统恶性肿瘤患者生存率行Cox风险分析,分析年龄、性别、移植年代、移植至诊断肿瘤时间、肿瘤病理分期、肿瘤诊断时移植肾功能、有无接受放化疗等辅助肿瘤治疗、有无抗淋巴细胞免疫球蛋白诱导治疗以及不同种类的基础免疫抑制剂等因素对肾移植受者泌尿及男性生殖系统恶性肿瘤生存率的影响。结果与普通人群相比,肾移植受者5年存活率明显降低(50%与68%),差异有统计学意义(P=0.02)。多因素分析表明肿瘤分期、接受放化疗等辅助治疗及年龄是影响患者生存的不利因素,而外科手术和肿瘤发病时移植肾功能正常则是保护性因素。结论与普通人群相比,移植受者发生泌尿及男性生殖系统恶性肿瘤的生存率明显降低。 展开更多
关键词 肾移植 泌尿生殖系统 免疫抑制剂
原文传递
Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms 被引量:6
14
作者 Yu-Hua Huang Ya-Qun Zhang Jiao-Ti Huang 《Asian Journal of Andrology》 SCIE CAS CSCD 2019年第3期291-295,共5页
Prostate cancer (PCa) is a major health risk for older men worldwide. Existing systemic therapies mostly target androgen receptor (AR). Although treatments are initially effective, the disease always recurs. A potenti... Prostate cancer (PCa) is a major health risk for older men worldwide. Existing systemic therapies mostly target androgen receptor (AR). Although treatments are initially effective, the disease always recurs. A potential mechanism for the treatment failure is that PCa contains, in addition to the AR-positive luminal type tumor cells, a small component of neuroendocrine (NE) cells. The function of NE cells in PCa remains poorly understood, and one important characteristic of these cells is their lack of expression of AR and resistance to hormonal therapy. In addition, many patients develop the more aggressive small-cell neuroendocrine carcinoma (SCNC) after hormonal therapy. Although this clinical phenomenon of disease transformation from adenocarcinoma to SCNC is well established, the cell of origin for SCNC remains unclear. Recently, loss of function of Rb and TP53 and amplification and overexpression of MYCN and Aurora A kinase have been identified as important biomarkers and potential disease drivers. In this article, we systematically review the histology of normal prostate and prostate cancer including the main histologic types: adenocarcinoma and SCNC. We also review the findings from many studies using cellular and animal models as well as human specimens that attempt to understand the molecular mechanisms of treatment failure, disease progression, and tumor transformation from adenocarcinoma to SCNC. 展开更多
关键词 ADENOcarcinoma NEUROENDOCRINE PROSTATE small-cell carcinoma
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部